FDA weighs new study requirements for Sarepta to confirm safety of gene therapy Elevidys: report
24th July 2025 Uncategorised 0Although Sarepta Therapeutics managed to defuse a brief stalemate with the FDA earlier this week, the U.S. drug regulator is reportedly going to put the company to work in order to affirm the safety of its Duchenne muscular dystrophy gene therapy Elevidys.
More: FDA weighs new study requirements for Sarepta to confirm safety of gene therapy Elevidys: report
Source: fierce